We are honored that Mural Health has been named a finalist for the 2025 SCOPE Summit Participant Engagement Award (PEA), for our work to make clinical trials more accessible and diverse through the Harley Jacobsen Clinical Trial Act.

In order to promote a more diverse trial population and drug development process, we need to make it possible for all Americans to participate. The Harley Jacobsen Act is a key step in that mission. Currently, the 110M Americans on a social welfare program are prevented from participating in trials, because those payments are very often mislabeled as taxable income, which threatens to disqualify low income Americans from receiving government benefits like Medicaid and SNAP. The Harley Jacobsen Act seeks to change this by excluding all payments to all participants in all clinical trials from being treated as taxable income.  

Watch a short discussion about the Harley Jacobsen Act with our founder and CEO, Sam Whitaker, below.

‍

‍

We’ll be sharing more about our finalist nomination in the weeks leading up to the 2025 SCOPE Summit (February 3-6 in Orlando) on our social media channels. If you’re attending, stop by booth 232 or schedule 15 minutes with our team by Clicking Here.